CClinicalTrials.gg
CompletedNCT01978834Updated Jan 29, 2015

Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer

An observational study in Osteoporosis, sponsored by Bone Index Finland Ltd. Completed at 1 site in United States. Open to female participants aged 50 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-29.

Sponsored by Bone Index Finland Ltd · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
560
Ages
50 Years to 89 Years
Sex
Female
01

Study summary

This study is designed for clinical validation of the novel ultrasound device (Bindex®, Bone Index Finland Ltd.). In a preliminary study technique has been validated in Finnish elderly woman population with 285 healthy and 56 osteoporotic subjects (n = 341 in total). Significant and good correlation was observed between Density Index (DI) determined with Bindex and femoral bone mineral density determined with DXA (r = 0.65 - 0.70). In addition, with determination of 90% sensitivity and specificity thresholds, significant number (65-75%) of patients could be diagnosed without additional verification with DXA.

First, the thresholds for DI will be determined by measuring 70 osteoporotic and 70 healthy patients (n = 140) with Bindex and DXA within four decades of age; age 50 to 59 years, age 60 to 69 years, age 70 to 79 years, and age 80 to 89 years. The feasibility of DI for diagnostics of osteoporosis and evaluation of bone mineral density (BMD) will be assessed. The thresholds for the BMD estimate obtained with DI will be determined for osteoporotic and non-osteoporotic patients. For fracture risk assessment, DI measurements are used to predict the outcome of currently available fracture risk assessment tools.

  1. To investigate optimal configuration of ultrasound parameters and patient characteristics for prediction of proximal femur and lumbar spine BMD for women in each four decades of age; 50 to 59 years, 60 to 69 years, 70 to 79 years, and 80-89 years.
  2. To develop national diagnostic thresholds for DI in prediction of osteoporosis status with a reference female population (American-Caucasian) in each four decades of age; 50 to 59 years, 60 to 69 years, 70 to 79 years, and 80-89 years.
Read the detailed description

Data will be stored by Park Nicollet Institute. Only data listed below will be given to the research team at Bindex for analyses.

The data for determination of diagnostic threshold for DI in North American population will be analyzed by Bone Index Finland. The data will include following parameters:

  • Age in years
  • Weight
  • Height
  • Cortical thickness values at each location
  • Density Index values
  • Raw data on ultrasound signals.
  • DXA measurement data
  • Identification code (Uniquely created identification code given to a subject, does not carry any information on subject but enables tracing if needed.)
  • Data from Appendix A, excluding patient name and medical record number

Risk factors will be collected in a separate questionnaire (Appendix A).

  1. Name
  2. Medical Record Number
  3. Weight (kg)
  4. Height (cm)
  5. Chair Stand test Can do easily; can do only with difficulty; cannot do

    Risk Factors:

  6. Previous fracture (Skeletal site, age at which fracture occured)
  7. Parent fractured hip (Yes, No)
  8. Current smoking (Yes, No)
  9. Glucocorticoid Use (Yes, No)
  10. Rheumatoid arthritis (Yes, No)
  11. Alcohol 3 or more units per day (Yes, No)
  12. Osteoporosis medication, type (e.g. alendronate, bisphosphonates), start- and end-date (Within the past five years)
02

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • Osteoporosis, diagnosis, ultrasound
03

In context

Osteoporosis

1,640 studies on the registry are indexed under Osteoporosis; 212 are open to participants now.

This study's enrollment of 560 is above the median of 174 across 446 observational studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Bone Index Finland Ltd is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Female (American-Caucasian)

Inclusion criteria

  • Female sex
  • Age 50 to 89 years

Exclusion criteria

Exclusion Criteria:

  • Those who have opted out of being contacted for research on their general Park Nicollet clinic consent will not be recruited by mail
  • Inability to sign consent form due to cognitive impairment. Those with dementia (ICD-9 diagnosis codes 331.0, 294.1, 294.10, 294.11, or 294.8) will excluded from mailed recruitment
  • Measurement of hip BMD is not feasible (for example, those who have had bilateral hip replacement surgeries or who cannot have central DXA because of their body weight)
  • Open leg or arm wounds at sites where ultrasound measurements are supposed to be taken, precluding such measurements
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
560 participants (actual)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Thresholds for Bindex in Osteoporosis Diagnostics

    Diagnostics thresholds for DI parameter for Osteoporosis within four decades of age; age 50 to 59 years, age 60 to 69 years, age 70 to 79 years, and age 80 to 89 years.

    Time frame: 1 year

07

Study locations

1 site
  • Park Nicollet Institute
    Minneapolis, Minnesota 55416, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01978834
Lead sponsor
Bone Index Finland Ltd
Collaborators
HealthPartners Institute
Responsible party
Sponsor
First posted
Nov 8, 2013
Start date
Oct 2013
Primary completion
Oct 2014
Completion
Oct 2014
Last update
Jan 29, 2015

Study contacts

John T Schousboe, MD, PhD
principal investigator · HealthPartners Institute
Janne P Karjalainen, PhD
study director · Bone Index Finland Ltd
Ossi Riekkinen, PhD
study director · Bone Index Finland Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion